GlassScriptPhysician profile
Jonathan K Williams
NPI 1821253683
$3,866.08
in general payments reported to CMS, 2019-2025
42 companies · $739 in 2025
The $739 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $976 · 2022: $631 · 2023: $753 · 2024: $768 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209 · Entertainment: $30.83 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,208.54 |
| Entertainment | $30.83 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $586.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $318.37 | 2021-2025 | |
| Abbott Laboratories | $292.27 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.41 | 2021-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $277.57 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $204.08 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $170.46 | 2021-2023 | |
| Insulet Corporation | $164.35 | 2023-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $151.46 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $107.44 | 2021-2025 | Tepezza, Evenity |
| Ascendis Pharma Endocrinology INC | $105.28 | 2023-2025 | Yorvipath, Skytrofa |
| Astrazeneca Pharmaceuticals LP | $92.08 | 2021-2023 | Lokelma |
| Corcept Therapeutics | $75.75 | 2021-2024 | Korlym |
| Neurocrine Biosciences, INC. | $74.61 | 2024-2025 | |
| Medtronic, INC. | $73.32 | 2023-2024 | Minimed 780g, Intellis Adaptivestim |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $72.68 | 2021-2024 | Isturisa, Signifor Lar |
| Radius Health, INC. | $68.46 | 2021-2024 | Tymlos |
| Abbvie INC. | $67.29 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $61.77 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $51.69 | 2021-2022 | |
| Madrigal Pharmaceuticals | $50.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Amarin Pharma, INC. | $48.01 | 2021 | |
| Pfizer INC. | $46.65 | 2023 | |
| Horizon Therapeutics Plc | $39.02 | 2021-2023 | Tepezza |
| Eton Pharmaceuticals, INC. | $33.60 | 2024-2025 | Alkindi, Increlex, Khindivi |
| Amryt Pharma Holdings LTD | $33.38 | 2022-2023 | Myalept |
| Inspire Medical Systems, INC. | $33.10 | 2023 | Inspire |
| Nestle Healthcare Nutrition INC. | $32.62 | 2021 | |
| Optos, INC. | $30.83 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Kyowa Kirin, INC. | $28.44 | 2023-2024 | Crysvita |
| Aimmune Therapeutics, INC. | $21.77 | 2024 | |
| Chiesi USA, INC. | $20.71 | 2025 | Mycapssa |
| Alnylam Pharmaceuticals INC. | $19.92 | 2022 | |
| Tolmar, INC. | $18.90 | 2025 | Fensolvi |
| Beta Bionics, INC. | $17.10 | 2024 | Ilet Bionic Pancreas |
| Biomarin Pharmaceutical INC. | $16.46 | 2024 | Voxzogo 1.2mg |
| Eusa Pharma (US) LLC | $14.87 | 2022 | |
| Tandem Diabetes Care, INC. | $14.26 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $13.35 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.87 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.82 | 2023 | Quviviq |
| Ibsa Pharma INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.